Company intelligence / Profile preview

Kathera Bioscience

Union, New Jersey, United Stateskatherabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

No clinical trial data reported yet; currently funded through NIH SBIR grants to advance preclinical programs targeting novel antifungal mechanisms[1][2][3].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules targeting fungal enzymes involved in growth and pathogenicity pathways
Industry: Biotech

Drug pipeline

1 asset

TRB-N0224

Pre-clinical

Indications: Life-threatening fungal infections

Partnerships

Located at Institute for Life Science Entrepreneurship (ILSE), Kean University, incubated there with academic collaboration from SUNY-Upstate Medical University[2][3]. No major pharma partnerships publicly listed.

Beyond the preview

Go deeper on Kathera Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kathera Bioscience.

Explore the full profile